RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, announced today the close of a $15 million Series A financing co-led by SPRIM ...
By limiting joint damage, disability is reduced. The primary treatment for rheumatoid arthritis is medication to reduce immune system activity and inflammation. Five categories of drugs commonly used ...
Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA). Different parts of the immune system have been targeted by monoclonal ...